160 related articles for article (PubMed ID: 37565973)
1. Age, Sex, and Outcomes in Heart Failure With Reduced EF: Insights From the VICTORIA Trial.
Lam CSP; Piña IL; Zheng Y; Bonderman D; Pouleur AC; Saldarriaga C; Pieske B; Blaustein RO; Nkulikiyinka R; Westerhout CM; Armstrong PW;
JACC Heart Fail; 2023 Sep; 11(9):1246-1257. PubMed ID: 37565973
[TBL] [Abstract][Full Text] [Related]
2. Ejection Fraction, Biomarkers, and Outcomes and Impact of Vericiguat on Outcomes Across EF in VICTORIA.
Butler J; Zheng Y; Khan MS; Bonderman D; Lund LH; deFilippi CR; Blaustein RO; Ezekowitz JA; Freitas C; Hernandez AF; O'Connor CM; Voors AA; Westerhout CM; Lam CSP; Armstrong PW;
JACC Heart Fail; 2023 May; 11(5):583-592. PubMed ID: 37137660
[TBL] [Abstract][Full Text] [Related]
3. N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes: Vericiguat Heart Failure With Reduced Ejection Fraction Study.
Ezekowitz JA; O'Connor CM; Troughton RW; Alemayehu WG; Westerhout CM; Voors AA; Butler J; Lam CSP; Ponikowski P; Emdin M; Patel MJ; Pieske B; Roessig L; Hernandez AF; Armstrong PW
JACC Heart Fail; 2020 Nov; 8(11):931-939. PubMed ID: 33039447
[TBL] [Abstract][Full Text] [Related]
4. Recurrent Hospitalizations and Response to Vericiguat in Heart Failure and Reduced Ejection Fraction.
Mentz RJ; Stebbins A; Butler J; Chiang CE; Ezekowitz JA; Hernandez AF; Hilkert R; Lam CSP; McDonald K; O'Connor CM; Pieske B; Ponikowski P; Roessig L; Sweitzer NK; Voors AA; Anstrom KJ; Armstrong PW;
JACC Heart Fail; 2024 May; 12(5):839-846. PubMed ID: 38363272
[TBL] [Abstract][Full Text] [Related]
5. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator: The VICTORIA Trial.
Armstrong PW; Roessig L; Patel MJ; Anstrom KJ; Butler J; Voors AA; Lam CSP; Ponikowski P; Temple T; Pieske B; Ezekowitz J; Hernandez AF; Koglin J; O'Connor CM
JACC Heart Fail; 2018 Feb; 6(2):96-104. PubMed ID: 29032136
[TBL] [Abstract][Full Text] [Related]
6. Clinical Outcomes and Response to Vericiguat According to Index Heart Failure Event: Insights From the VICTORIA Trial.
Lam CSP; Giczewska A; Sliwa K; Edelmann F; Refsgaard J; Bocchi E; Ezekowitz JA; Hernandez AF; O'Connor CM; Roessig L; Patel MJ; Pieske B; Anstrom KJ; Armstrong PW;
JAMA Cardiol; 2021 Jun; 6(6):706-712. PubMed ID: 33185650
[TBL] [Abstract][Full Text] [Related]
7. Epidemiology of Worsening Heart Failure in a Population-based Cohort from Alberta, Canada: Evaluating Eligibility for Treatment With Vericiguat.
Sepehrvand N; Islam S; Dover DC; Kaul P; McAlister FA; Armstrong PW; Ezekowitz JA
J Card Fail; 2022 Aug; 28(8):1298-1308. PubMed ID: 35589087
[TBL] [Abstract][Full Text] [Related]
8. Relationship between baseline electrocardiographic measurements and outcomes in patients with high-risk heart failure: Insights from the VerICiguaT Global Study in Subjects with Heart Failure with Reduced Ejection Fraction (VICTORIA) trial.
Yogasundaram H; Zheng Y; Ly E; Ezekowitz J; Ponikowski P; Lam CSP; O'Connor C; Blaustein RO; Roessig L; Temple T; Westerhout CM; Armstrong PW; Sandhu RK;
Eur J Heart Fail; 2023 Oct; 25(10):1822-1830. PubMed ID: 37655679
[TBL] [Abstract][Full Text] [Related]
9. Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial.
Pieske B; Patel MJ; Westerhout CM; Anstrom KJ; Butler J; Ezekowitz J; Hernandez AF; Koglin J; Lam CSP; Ponikowski P; Roessig L; Voors AA; O'Connor CM; Armstrong PW;
Eur J Heart Fail; 2019 Dec; 21(12):1596-1604. PubMed ID: 31820546
[TBL] [Abstract][Full Text] [Related]
10. Assessment of Biomarkers of Myocardial injury, Inflammation, and Renal Function in Heart Failure With Reduced Ejection Fraction: The VICTORIA Biomarker Substudy.
Defilippi CR; Alemayehu WG; Voors AA; Kaye D; Blaustein RO; Butler J; Ezekowitz JA; Hernandez AF; Lam CSP; Roessig L; Seliger S; Shah P; Westerhout CM; Armstrong PW; O'Connor CM;
J Card Fail; 2023 Apr; 29(4):448-458. PubMed ID: 36634811
[TBL] [Abstract][Full Text] [Related]
11. Drug Treatment of Heart Failure with Reduced Ejection Fraction: Defining the Role of Vericiguat.
Coats AJS; Tolppanen H
Drugs; 2021 Sep; 81(14):1599-1604. PubMed ID: 34478114
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan: insights from the VICTORIA trial.
Senni M; Alemayehu WG; Sim D; Edelmann F; Butler J; Ezekowitz J; Hernandez AF; Lam CSP; O'Connor CM; Pieske B; Ponikowski P; Roessig L; Voors AA; Westerhout CM; McMullan C; Armstrong PW;
Eur J Heart Fail; 2022 Sep; 24(9):1614-1622. PubMed ID: 35791083
[TBL] [Abstract][Full Text] [Related]
13. Blood Pressure and Safety Events With Vericiguat in the VICTORIA Trial.
Lam CSP; Mulder H; Lopatin Y; Vazquez-Tanus JB; Siu D; Ezekowitz J; Pieske B; O'Connor CM; Roessig L; Patel MJ; Anstrom KJ; Hernandez AF; Armstrong PW;
J Am Heart Assoc; 2021 Nov; 10(22):e021094. PubMed ID: 34743540
[TBL] [Abstract][Full Text] [Related]
14. Vericiguat and NT-proBNP in patients with heart failure with reduced ejection fraction: analyses from the VICTORIA trial.
Senni M; Lopez-Sendon J; Cohen-Solal A; Ponikowski P; Nkulikiyinka R; Freitas C; Vlajnic VM; Roessig L; Pieske B
ESC Heart Fail; 2022 Dec; 9(6):3791-3803. PubMed ID: 35880474
[TBL] [Abstract][Full Text] [Related]
15. Vericiguat and Cardiovascular Outcomes in Heart Failure by Baseline Diabetes Status: Insights From the VICTORIA Trial.
Khan MS; Butler J; Young R; Lewis BS; Escobedo J; Refsgaard J; Reyes E; Roessig L; Blaustein RO; Lam CSP; Voors AA; Ponikowski P; Anstrom KJ; Armstrong PW;
JACC Heart Fail; 2024 Jun; ():. PubMed ID: 38934967
[TBL] [Abstract][Full Text] [Related]
16. Cost-Effectiveness of Vericiguat in Patients With Heart Failure With Reduced Ejection Fraction: The VICTORIA Randomized Clinical Trial.
Chew DS; Li Y; Bigelow R; Cowper PA; Anstrom KJ; Daniels MR; Davidson-Ray L; Hernandez AF; O'Connor CM; Armstrong PW; Mark DB;
Circulation; 2023 Oct; 148(14):1087-1098. PubMed ID: 37671551
[TBL] [Abstract][Full Text] [Related]
17. Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA (Vericiguat Global Study in Subjects with HFrEF) trial.
Voors AA; Mulder H; Reyes E; Cowie MR; Lassus J; Hernandez AF; Ezekowitz JA; Butler J; O'Connor CM; Koglin J; Lam CSP; Pieske B; Roessig L; Ponikowski P; Anstrom KJ; Armstrong PW;
Eur J Heart Fail; 2021 Aug; 23(8):1313-1321. PubMed ID: 33999486
[TBL] [Abstract][Full Text] [Related]
18. Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study.
Pieske B; Maggioni AP; Lam CSP; Pieske-Kraigher E; Filippatos G; Butler J; Ponikowski P; Shah SJ; Solomon SD; Scalise AV; Mueller K; Roessig L; Gheorghiade M
Eur Heart J; 2017 Apr; 38(15):1119-1127. PubMed ID: 28369340
[TBL] [Abstract][Full Text] [Related]
19. Sequential Evaluation of NT-proBNP in Heart Failure: Insights Into Clinical Outcomes and Efficacy of Vericiguat.
Armstrong PW; Zheng Y; Troughton RW; Lund LH; Zhang J; Lam CSP; Westerhout CM; Blaustein RO; Butler J; Hernandez AF; Roessig L; O'Connor CM; Voors AA; Ezekowitz JA;
JACC Heart Fail; 2022 Sep; 10(9):677-688. PubMed ID: 36049817
[TBL] [Abstract][Full Text] [Related]
20. Effect of vericiguat on left ventricular structure and function in patients with heart failure with reduced ejection fraction: The VICTORIA echocardiographic substudy.
Pieske B; Pieske-Kraigher E; Lam CSP; Melenovský V; Sliwa K; Lopatin Y; Arango JL; Bahit MC; O'Connor CM; Patel MJ; Roessig L; Morris DA; Kropf M; Westerhout CM; Zheng Y; Armstrong PW;
Eur J Heart Fail; 2023 Jul; 25(7):1012-1021. PubMed ID: 36994634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
